Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania

Journal of Cardiovascular Emergencies

Lorenzovici László¹  Csanádi Marcell²  Farkas-Ráduly Szabolcs³  Székely Andrea³  Jitaru Ciprian⁴ 

[1] Faculty of Technical and Human Sciences, Sapientia University, Târgu Mureș, Romania;Syreon Research Institute, Budapest, Hungary;Syreon Research Romania, Târgu Mureș, Romania;Vifor Pharma Romania, Cluj-Napoca, Romania;

关键词: heart failure;    iron deficiency;    treatment cost;    budget impact;    ferric carboxymaltose;    romania;   

DOI  :  10.2478/jce-2019-0018

来源: DOAJ

【 摘 要 】

Background: Ferric carboxymaltose (FCM) treatment in case of iron deficient (ID) patients with chronic heart failure (CHF) has shown great promise according to the findings of recent studies in improvement of symptoms and quality of life, New York Heart Association (NYHA) classification, and exercise capacity.

【 授权许可】

Unknown